Remove Cell Biology Remove Engineering Remove Therapies
article thumbnail

Applications of engineered exosomes in drugging noncoding RNAs for cancer therapy

Chemical Biology and Drug Design

Exosome engineering can be conducted through surface and content modification of biological exosomes. In preisolation method, parental cells are stimulated to express some special genes like lncRNAs, miRNAs, and receptors to have the capacity to bind to the target cells and deliver their content.

article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells). NK cells can be readily extracted from umbilical cord blood or peripheral blood of adult donors.

Therapies 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patient-derived organoids in disease modelling

Drug Target Review

Two-dimensional cell models were the cornerstone of cellular assays in early drug discovery for years, yet the system lacks the genetic and epigenetic background of the patient and the cell-to-cell spatial architecture and cellular signalling between cells of different types within the tissue architecture.

Disease 122
article thumbnail

A T cell receptor immunotherapy against a novel target

Drug Target Review

How does Immunocore’s TCR technology differentiate itself from other approaches to targeted cancer therapy? Can you explain the mechanism of action by which ImmTAC molecules selectively target and kill cancer cells?

article thumbnail

Women in STEM with Juliet Williams

Drug Target Review

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. With these newer programs, I’ve had the honour of collaborating with my team to build a multi-faceted drug discovery engine.

article thumbnail

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

The Pharma Data

INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treatedwith a platinum-based therapy and PD-(L)1 inhibitor. Overall, the combination therapy data to date supports the expedited development of monalizumab and cetuximab in this indication. MARSEILLE, France, Oct.

article thumbnail

Cell and gene therapy development moves into cardiac indications

Drug Target Review

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. However, cell-based therapies are intended to leverage those healthy cells via transplant to regenerate damaged tissue.